Two weeks after the second dose of the coronavirus vaccine developed by Pfizer Inc in collaboration with BioNTech SE and Moderna Inc, the risk of infection is reduced by 90%, a new study noted.

According to Dailymail.co.uk, the results of a study by the US Centers for Disease Control and Prevention of the actual use of these messenger RNA (mRNA) vaccines confirm the findings of large controlled clinical trials conducted before they received an emergency use clearance from U.S. Food and Drug Administration.